PTCT PTC Therapeutics Inc.

0  0%
Previous Close 42.9
Price To Book 4.89
Market Cap 2,506,695,434
Shares 58,431,129
Volume 3
Short Ratio
Av. Daily Volume 832,551

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due 2H 2019.
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. Further CRL October 25, 2017. New trial initiated 4Q 2018.
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.
Nonsense mutation cystic fibrosis
NDA filing due 2H 2019.
Spinal Muscular Atrophy (SMA) Type 1
BLA filing due late-2019.
AADC deficiency
Phase 1 enrolment to be completed by the end of 2019.
Leiomyosarcoma (LMS)
Phase 1 enrolment to be completed by the end of 2019.
Diffuse Intrinsic Pontine Glioma (DIPG)
Phase 1 enrolment to be completed by the end of 2019.
Acute myeloid leukemia (AML)
FDA Approval announced for label expansion June 7, 2019.
Duchenne muscular dystrophy (age 2-5)

Latest News

  1. Did You Miss Therapeutics's (NASDAQ:PTCT) Whopping 511% Share Price Gain?
  2. Hedge Funds Have Never Been This Bullish On PTC Therapeutics, Inc. (PTCT)
  3. PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients
  4. PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age
  5. PTC Therapeutics Promotes Emily Hill to Chief Financial Officer
  6. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  7. PTC Therapeutics to Participate at Upcoming Investor Conference
  8. PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders
  9. PTC Therapeutics and MRI Interventions Announce Strategic Investment
  10. Edited Transcript of PTCT earnings conference call or presentation 2-May-19 8:30pm GMT
  11. PTC Therapeutics to Participate at Upcoming Investor Conferences
  12. This Biotech Has A 'Swing Factor' In SMA Drugs And It's Slugging Biogen
  13. Data from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients
  14. PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates
  15. PTC Therapeutics: 1Q Earnings Snapshot
  16. PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update
  17. Here is What Hedge Funds Think About PTC Therapeutics, Inc. (PTCT)
  18. Translarna™ (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy
  19. Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for